WPSS for Myelodysplastic Syndrome

The WHO classification-based Prognostic Scoring System (WPSS) is a clinical tool used to estimate prognosis in patients with myelodysplastic syndrome (MDS). It was designed to improve risk assessment by combining three variables that reflect disease biology and clinical burden: the WHO morphologic subtype, cytogenetic risk, and red blood cell transfusion dependence. Unlike the original IPSS, WPSS was developed as a dynamic model, meaning it can be applied not only at diagnosis but also during follow-up as a patient’s disease changes.

What WPSS measures

WPSS evaluates prognosis using three components:

1. WHO classification of MDS
2. Cytogenetic risk category
3. Dependence on regular RBC transfusions

These factors were shown to independently predict outcomes in MDS, including overall survival and the risk of leukemic progression. Transfusion dependence is especially important because it reflects more advanced marrow failure and has been associated with worse outcomes.

How the scoring works

In the classic WPSS, points are assigned as follows:

WHO subtype

• RA, RARS, isolated del(5q): 0
• RCMD, RCMD-RS: 1
• RAEB-1: 2
• RAEB-2: 3

Cytogenetics

• Good: 0
• Intermediate: 1
• Poor: 2

RBC transfusion dependence

• No: 0
• Yes: 1

The total score places patients into one of five risk groups:

• 0 = Very low
• 1 = Low
• 2 = Intermediate
• 3–4 = High
• 5–6 = Very high

Risk groups and median survival

Commonly cited median survival values for the classic WPSS are:

• Very low: about 141 months
• Low: about 66 months
• Intermediate: about 48 months
• High: about 26 months
• Very high: about 9 months

These figures are useful for broad prognostic counseling, but they should be interpreted as population-level estimates rather than exact predictions for an individual patient. Outcomes can vary based on age, comorbidities, treatment, molecular findings, and response to therapy.

Why WPSS matters

WPSS became important because it added two features that earlier systems handled less well. First, it incorporated the WHO morphologic classification, which captures disease features such as multilineage dysplasia and blast burden more precisely than older FAB-based schemes. Second, it included transfusion dependence, a clinically meaningful marker of disease severity. These additions made WPSS helpful for estimating both survival and risk of transformation to acute myeloid leukemia.

Another strength is that WPSS is time-dependent. Since MDS can evolve over time, a model that can be recalculated during follow-up is often more clinically useful than one restricted to diagnosis alone.

Clinical use

In practice, WPSS can help clinicians:

• stratify patients into prognostic groups,
• guide the intensity of monitoring,
• support discussions about expected disease course,
• inform treatment planning alongside other tools and clinical judgment.

That said, modern practice often relies heavily on IPSS-R and increasingly IPSS-M, which incorporate more detailed cytopenias and, in the case of IPSS-M, molecular genetics. WPSS remains historically important and still useful conceptually, especially because of its dynamic structure and emphasis on transfusion burden.

Limitations of WPSS

WPSS has several limitations:

• It was developed before the current era of broad molecular profiling, so it does not include somatic mutation data.
• It reflects older WHO subtype terminology, so mapping modern diagnostic categories to the classic score may require care. This is an inference based on the system’s reliance on older WHO categories and later changes in MDS classification.
• It does not capture the full depth of cytopenias as comprehensively as newer models such as IPSS-R.
• Its survival estimates come from cohort data and should not replace individualized assessment.

Summary

WPSS is a prognostic scoring system for MDS that combines WHO subtype, cytogenetic risk, and RBC transfusion dependence to classify patients into very low, low, intermediate, high, or very high risk groups. It was an important advance because it is dynamic and can be reassessed over time. Although newer systems are now more common, WPSS remains a useful and influential framework for understanding prognosis in MDS.